JPMorgan resumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating. The firm increased its price target for the stock from $515 to $560.
The upgrade follows Vertex's strategic acquisition of Crinetics, which strengthens its position in the endocrinology market. Analysts expect the Crinetics deal to contribute to revenue immediately.
Vertex maintains a GF Score of 87 out of 100, indicating high financial strength and growth. Current market analysis suggests the company is fair-valued or slightly undervalued.